Announcements Trials

Browse Landscape

Phase

Status

Completed 6 Active not recruiting 6 Unknown 4 Withdrawn 3 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 27 Genitourinary 13 Gastrointestinal 11 Head & Neck 6 Gynecologic 6 Lymphoid 5 Breast 5 Other solid neoplasm 4 Plasma cell 3 Endocrine 2 Tumor-Agnostic 1 Sarcoma 1 Other hematologic neoplasm 1 Myeloid 1 Dermatologic 1 Classical hematology 1 CNS 1

Conditions

Carcinoma, Merkel Cell 1

Interventions

pembrolizumab 58 Cyclophosphamide 53 Ipilimumab 52 Nivolumab 44 aldesleukin 35 Interleukin-2 26 fludarabine phosphate 22 fludarabine 21 Vemurafenib 20 Temozolomide 19 Radiotherapy 18 dabrafenib 15 trametinib 12 Radiosurgery 11 CTLA-4 Antigen 11 Filgrastim 10 Dacarbazine 10 spartalizumab 9 cobimetinib 9 binimetinib 9 atezolizumab 9 Biopsy 9 poly ICLC 8 Paclitaxel 8 Antilymphocyte Serum 8 encorafenib 7 avelumab 7 Rituximab 7 Introns 7 romidepsin 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × durvalumab × Dermatologic × Clear all

NCT06939036 2026-02-05

SANTANA-225

Ariceum Therapeutics GmbH

Phase 1/2 Terminated

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡